|Bid||1.3800 x 2900|
|Ask||1.4300 x 1400|
|Day's Range||1.3700 - 1.4500|
|52 Week Range||1.2000 - 2.1500|
|Beta (3Y Monthly)||0.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
Athersys, Inc. (ATHX) announced today that its collaborator in Japan, HEALIOS K.K. (“Healios”) received notification this week from the Pharmaceutical Affairs and Food Sanitation Council (“PAFSC”) that its acute respiratory distress syndrome (“ARDS”) clinical program using HLCM051 (MultiStem® Cell Therapy), will receive the orphan regenerative medicine designation from the Ministry of Health, Labour and Welfare within the next few weeks. This designation may be given to investigational products being evaluated for indications that have a high unmet medical need and that occur in less than 50,000 patients in Japan.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
CLEVELAND, Nov. 06, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2019. Highlights of the third quarter.
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
CLEVELAND, Oct. 14, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6,.
Athersys, Inc. (ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2nd -4th in Carlsbad, California. Dr. Van Bokkelen will provide a brief overview of the Company’s mission and its therapeutic platform, MultiStem® cell therapy. The presentation will include information on the critical care indications in the Company’s progressing clinical pipeline, including the ongoing Phase 3 trial of MultiStem cell therapy for the treatment of ischemic stroke that has received Fast Track and Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration and positive scientific advice from the European Medicines Agency, and is being conducted under a Special Protocol Assessment.
CLEVELAND, Aug. 07, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2019. Highlights of the second quarter of.
CLEVELAND, July 08, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7,.
Athersys, Inc. (ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van Bokkelen’s presentation will take place at 11 AM Eastern Time on June 7, 2019 and will focus on the Company’s mission and the clinical development of its MultiStem® cell therapy. The talk will also summarize the recent positive data from its exploratory Phase 1/2 clinical study evaluating MultiStem cell therapy for the treatment acute respiratory distress syndrome (ARDS), and the ARDS clinical program has received Fast Track designation from the U.S. Food and Drug Administration for the next phase of development.
CLEVELAND, May 28, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy.
While it may not be enough for some shareholders, we think it is good to see the Athersys, Inc. (NASDAQ:ATHX) share...
Athersys, Inc. (ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the longest running, large-scale conference in the world offering groundbreaking research in pulmonary, critical care and sleep medicine.
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
CLEVELAND, May 08, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. ...